Schizophrenia Research
Volume 101, Issue 1 , Pages 266-272 , April 2008

Metabolic syndrome in first episode schizophrenia — A randomized double-blind controlled, short-term prospective study

  • Sahoo Saddichha

      Affiliations

    • National Tobacco Control Program, Swasthya Bhavan, Sector V, Kolkata, India
    • Corresponding Author InformationCorresponding author. Cell.: +91 9836530262.
    • ,
  • Narayana Manjunatha

      Affiliations

    • Central Institute of Psychiatry, Ranchi, India
    • ,
  • Shahul Ameen

      Affiliations

    • St. John's Hospital, Kattappana, Idukki, Kerala, India
    • ,
  • Sayeed Akhtar

      Affiliations

    • Central Institute of Psychiatry, Ranchi, India

Received 10 October 2007 ,Revised 23 December 2007 ,Accepted 4 January 2008.

References 

  1. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J CLAMORS Study Collaborative Group. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr. Res. 2007;90(1–3):162–173
  2. Brugha TS, Wing JK, Smith BL. Physical health of the long-term mentally ill in the community: is there unmet need?. Br. J. Psychiatry. 1989;155(6):777–781
  3. Chan HY, Chen CH, Chen JJ, Sun HJ, Chiu HJ, Chang CJ. A comparison of olanzapine and risperidone for the schizophrenic patients intolerance of neuroleptic-induced extrapyramidal syndromes. J. Eur. Coll. Neuropsychopharmacology. 2003;13(4):S316; as cited in Jayaram MB, Hosalli P, Stroup S. Risperidone versus olanzapine for schizophrenia (Review). The Cochrane Library 2007, Issue 1, The Cochrane Collaboration. John Wiley & Sons, Ltd
  4. De Hert M, van Eyck D, De Nayer A. Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int. Clin. Psychopharmacol. 2006;21(S2):S11–S15
  5. De Hert MA, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr. Res. 2006;83(1):87–93
  6. De Nayer A, De Hert M, Scheen A, Van Gaal L, Peuskens J. Conference report: Belgian consensus on metabolic problems associated with second-generation antipsychotics. Int. J. Psychiatry Clin. Pract. 2005;9(2):130–137
  7. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415–1428
  8. Grundy SM, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–239
  9. Gu , et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet. 2005;365(9468):1398–1405
  10. Haupt DW. Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol. 2006;16(S3):S149–S155
  11. IDF . The IDF Consensus Worldwide Definition of the Metabolic Syndrome. Brussels: International Diabetes Federation; 2005;available at www.idf.org
  12. Kendrick T. Cardiovascular and respiratory risk factors and symptoms among general practice patients with long-term mental illness. Br. J. Psychiatry. 1996;169(6):733–739
  13. Levitt NS, Lambert EV. The foetal origins of the metabolic syndrome — a South African perspective. Cardiovasc. J. S. Afr. 2002;13(4):179–180
  14. Lieberman JA. Metabolic changes associated with antipsychotic use. Prim. Care Companion J. Clin. Psychiat. 2004;6(S2):8–13
  15. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am. J. Psychiatry. 2004;161(8):1334–1349
  16. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 2005;80(1):19–32
  17. Methods in Human Nutritional Assessment-Estimating daily energy requirements available at http://people.brandeis.edu/~rgodoy/NSfTraining/Fieldmethods-diet&activity-2005.pdf.
  18. Meyer JM, et al. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr. Res. 2005;80(1):9–18
  19. Misra A, Wasir JS, Vikram NK. Waist circumference criteria for the diagnosis of abdominal obesity are not applicable uniformly to all populations and ethnic groups. Nutrition. 2005;21(9):969–976
  20. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can. J. Psychiatry. 2006;51(8):480–491
  21. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry. 2002;59(4):337–345
  22. Perloff D, Grim C, Flack J, et al. Human blood pressure determination by sphygmomanometry. Circulation. 1993;88(5):2460–2470
  23. Rakugi H, Ogihara T. The metabolic syndrome in the Asian population. Curr. Hypertens. Rep. 2005;7(2):103–109
  24. Reaven GM. Banting Lecture: role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-607
  25. Saari KM, Lindeman SM, Viilo KM, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J. Clin. Psychiatry. 2005;66(5):559-63
  26. Saddichha S, Ameen S, Akhtar S. Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode schizophrenia: a six-week prospective study in Indian female patients. Schizophr. Res. 2007;95(1–3):247
  27. Saddichha S, Mishra B, Akhtar S. Dose dependent acute excessive weight gain and metabolic changes in a drug naïve patient on risperidone are reversible with discontinuation: a case report. Br. J. Clin. Pharmacol. 2007;64(5):715-6
  28. Saw SM. The epidemiology of obesity: a review. Ann. Acad. Med. Singapore. 1997;26(4):489–493
  29. Shirzadi AA, Ghaemi SN. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv. Rev. Psychiatr. 2006;14(3):152–164
  30. Thakore J, Mann J, Vlahos I, Martin A, Reznek R. Increased visceral fat distribution in drug-naïve and drug free patients with schizophrenia. Int. J. Obes. Relat. Metab. Disord. 2002;26(1):137–141
  31. Thakore JH. Metabolic disturbance in first-episode schizophrenia. Br. J. Psychiatry. 2004;184(S47):76–79
  32. Toalson P, et al. The metabolic syndrome in patients with severe mental illnesses. Prim. Care Companion J. Clin. Psychiat. 2004;6(4):152–158
  33. World Medical Association . Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 2000;Available at http://www.wma.net

PII: S0920-9964(08)00051-0

doi: 10.1016/j.schres.2008.01.004

Schizophrenia Research
Volume 101, Issue 1 , Pages 266-272 , April 2008

Article Tools